United States Patent (19) 11 Patent Number: 5,919,452 Le Et Al
USOO59 19452A United States Patent (19) 11 Patent Number: 5,919,452 Le et al. (45) Date of Patent: *Jul. 6, 1999 54 METHODS OF TREATING TNFo-MEDIATED 92.16553 10/1992 WIPO. DISEASE USING CHMERIC ANT-TNF WO 93/02108 2/1993 WIPO. ANTIBODIES OTHER PUBLICATIONS 75 Inventors: Junming Le, Jackson Heights; Jan Shalaby, M.R. et al. Transplantation. 47:1057-1061, Jun. Vilcek, New York, both of N.Y.; Peter 1989. Dadonna, Palo Alto, Calif.; John Natanson, C. et al. Annals of Internal Medicine. Ghrayeb, Thorndale; David Knight, 120(9):771–783, May 1994. Berwyn, both of Pa.; Scott Seigal, Sun et al., Journal of Clinical Investigation, Vol. Westborough, Mass. 81:1328–1331, “Bowel Necrosis Induced by Tumor Necro sis Factor in Rats Is Mediated by Platelet-activating Factor”, 73 Assignees: New York University, New York, N.Y.; May 1988. Centocor, Inc., Malvern, Pa. Murch et al., Gut, vol. 32:913–917, "Serum concentrations of Tumour Necrosis Factor alpha in Childhood Chronic * Notice: This patent is Subject to a terminal dis Inflammatory Bowel Disease”, 1991. claimer. DerkX et al., The Lancet, vol. 342:173-174, Tumour-necro Sis-factor antibody treatement In Crogn's disease, Jul. 17, 1993. 21 Appl. No.: 08/192,861 Rademacher et al., Seminars in Immunopathology, Vol. 10:231-249, “Role of IgG Glycoforms in the Pathogenesis 22 Filed: Feb. 4, 1994 of Rheumatoid Arthritis', 1988. Lichtenstein et al., Current Opinions in Gastroenterology, Related U.S. Application Data vol. 8(4):655-662, “Clinical Advances in Inflammatory 63 Continuation-in-part of application No.
[Show full text]